Polycystic Ovary Syndrome: Metabolic Risk and Treatment Algorithm
Diagnostic Criteria: The 2023 Update
The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS (endorsed by ESHRE, ASRM, and the Endocrine Society) maintains the Rotterdam criteria requiring 2 of 3 features: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology (PCOM) on ultrasound (defined as follicle number per ovary of 20 or more using transducers with frequency of 8 MHz or higher, or ovarian volume above 10 mL). Key updates include elimination of PCOM as a diagnostic criterion in adolescents (within 8 years of menarche), where diagnosis requires both oligo-anovulation and hyperandrogenism. Anti-Mullerian hormone (AMH) above age-specific thresholds is now accepted as an alternative to ultrasound for PCOM detection in adults.
Metabolic Risk Assessment
Women with PCOS have a 2-4 fold increased risk of type 2 diabetes, with a conversion rate of 5-10% per year in those with impaired glucose tolerance. The guideline mandates oral glucose tolerance test (75g OGTT) at diagnosis regardless of BMI, repeated every 1-3 years based on risk factors. Metabolic syndrome prevalence is 30-40% in PCOS cohorts. Additional screening includes fasting lipid panel (dyslipidemia in 70% of PCOS patients), blood pressure, and assessment for obstructive sleep apnea (STOP-BANG questionnaire) in overweight/obese patients. Non-alcoholic fatty liver disease screening with ALT is recommended given the 3-fold increased prevalence in PCOS.
Lifestyle Intervention: First-Line for All
Structured lifestyle intervention is first-line therapy for all PCOS patients regardless of BMI. A modest weight loss of 5-10% improves menstrual regularity in 50-60% of overweight patients and restores ovulation in approximately 30%. The guideline recommends 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week plus 2 sessions of resistance training. The specific dietary pattern matters less than caloric deficit; Mediterranean, DASH, and standard energy-restricted diets all show comparable metabolic improvements. Behavioral support and psychological interventions for the high rates of anxiety (34%) and depression (40%) are now explicitly recommended.
Sponsored
Pharmacotherapy: Menstrual Regulation and Hyperandrogenism
Combined oral contraceptives (COCs) remain first-line for menstrual regulation and hyperandrogenism management. Low-dose formulations (20-35 mcg ethinyl estradiol) are preferred, with anti-androgenic progestins (cyproterone acetate, drospirenone, chlormadinone) offering additional hirsutism benefit. Metformin (1500-2000 mg daily) is recommended as adjunctive therapy for metabolic features, with a meta-analysis showing HbA1c reduction of 0.3% and 2-3 kg weight loss over 6 months. Spironolactone (50-200 mg daily) is the primary anti-androgen for hirsutism refractory to COCs after 6 months, with efficacy rates of 70-80% at 12 months but absolute contraception requirement due to teratogenicity.
Fertility Management Algorithm
Letrozole 2.5-7.5 mg daily (cycle days 3-7) is now unequivocally first-line for ovulation induction in PCOS, replacing clomiphene citrate based on the NICHD RMN trial showing higher live birth rates (27.5% versus 19.1%, p=0.007) and lower multiple pregnancy rates (3.4% versus 7.4%). Clomiphene citrate 50-150 mg daily remains second-line. Gonadotropins (low-dose step-up protocol starting at 37.5-50 IU FSH daily) are third-line due to higher cost and OHSS risk. In vitro maturation (IVM) is an emerging alternative for patients who are poor responders or wish to avoid OHSS risk, with recent meta-analyses showing live birth rates per cycle of 20-25%, approaching conventional IVF in experienced centers.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.